BRPI0512745A - métodos de genotipagem e de caracterizar um agente e kit - Google Patents

métodos de genotipagem e de caracterizar um agente e kit

Info

Publication number
BRPI0512745A
BRPI0512745A BRPI0512745-9A BRPI0512745A BRPI0512745A BR PI0512745 A BRPI0512745 A BR PI0512745A BR PI0512745 A BRPI0512745 A BR PI0512745A BR PI0512745 A BRPI0512745 A BR PI0512745A
Authority
BR
Brazil
Prior art keywords
agent
kit
characterize
methods
genotyping methods
Prior art date
Application number
BRPI0512745-9A
Other languages
English (en)
Inventor
Poulabi Banerjee
Karen Lynne Houseknecht
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0512745A publication Critical patent/BRPI0512745A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MéTODOS DE GENOTIPAGEM E DE CARACTERIZAR UM AGENTE E KIT. A presente invenção refere-se a métodos de genotipagem, métodos de tratamento, testes diagnósticos e métodos de caracterizar um agente, relacionado a um polimorfismo de nucleotídeo único do gene GPR40.
BRPI0512745-9A 2004-06-30 2005-06-20 métodos de genotipagem e de caracterizar um agente e kit BRPI0512745A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58468604P 2004-06-30 2004-06-30
US11/046,020 US20060003344A1 (en) 2004-06-30 2005-01-28 Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
PCT/IB2005/001962 WO2006006062A1 (en) 2004-06-30 2005-06-20 Methods related to a single nucleotide polymorphism of the g protein coupled receptor, gpr40

Publications (1)

Publication Number Publication Date
BRPI0512745A true BRPI0512745A (pt) 2008-04-08

Family

ID=35514424

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512745-9A BRPI0512745A (pt) 2004-06-30 2005-06-20 métodos de genotipagem e de caracterizar um agente e kit

Country Status (10)

Country Link
US (1) US20060003344A1 (pt)
EP (1) EP1763585A1 (pt)
JP (1) JP2008504836A (pt)
AU (1) AU2005261437A1 (pt)
BR (1) BRPI0512745A (pt)
CA (1) CA2570921A1 (pt)
IL (1) IL179911A0 (pt)
MX (1) MXPA06014024A (pt)
NO (1) NO20070521L (pt)
WO (1) WO2006006062A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EA011010B1 (ru) * 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1924546A1 (en) * 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
US7687526B2 (en) * 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AU2007293028B2 (en) * 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
JP2008195625A (ja) * 2007-02-08 2008-08-28 Pharma Frontier Kk Ｇ蛋白質共役型レセプター抑制剤および医薬
CA2683751C (en) * 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
US8450522B2 (en) * 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) * 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US7214495B2 (en) * 2002-02-14 2007-05-08 Takeda Pharmaceutical Company Limited Screening method

Also Published As

Publication number Publication date
JP2008504836A (ja) 2008-02-21
US20060003344A1 (en) 2006-01-05
CA2570921A1 (en) 2006-01-19
MXPA06014024A (es) 2007-02-08
EP1763585A1 (en) 2007-03-21
IL179911A0 (en) 2007-05-15
WO2006006062A1 (en) 2006-01-19
AU2005261437A1 (en) 2006-01-19
NO20070521L (no) 2007-01-26

Similar Documents

Publication Publication Date Title
NO20070521L (no) Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40
DK1597391T3 (da) Anvendelse af intron-RNA til måling af genekspression
CY1111755T1 (el) Μεθοδοι και συνθεσεις για μειωση ποσοτητων ιικου γονιδιωματος hcv σε ενα κυτταρο στοχο
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
EP1810026A4 (en) B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
ATE408032T1 (de) Esr1 und gebärmutterhalskrebs
JP2009538607A5 (pt)
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
MY155340A (en) Use of cathepsin c
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
WO2007058968A3 (en) Gene expression profiles and methods of use
ATE490339T1 (de) Diagnostikum für osteoporose
WO2007084359A3 (en) Compositions and methods for the treatment of influenza infection
WO2005056839A3 (de) Primer und sonden zum nachweis genitaler hpv-genotypen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.